Meredith Holub, DO
Pulmonary Disease · Hartford, CTNPI 1164817581
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Boehringer Ingelheim accounts for 70.1% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $10,868, more than ten times the $100 reported in 2019.
Across 270 payments — averaging $53.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$10K
- AstraZeneca$2K
- GSK$1K
- Mallinckrodt Hospital Products Inc.$249
- Mylan Specialty L.p.$217
- Amgen$167
- plus $643 from 10 others
What the payments were for
- Consulting fees$6,07542%
- Travel & lodging$3,13122%
- Food & beverage$4,94334%
- Education$3012%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 42 | $10,125 |
| AstraZeneca(2 entities) | 73 | $1,561 |
| GSK | 104 | $1,488 |
| Mallinckrodt Hospital Products Inc. | 5 | $249 |
| Mylan Specialty L.p. | 10 | $217 |
| Amgen | 7 | $167 |
| Regeneron Healthcare Solutions, Inc. | 8 | $152 |
| Harmony Biosciences LLC | 7 | $130 |
| Genentech USA, Inc. | 1 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $82 |
| Grifols USA, LLC | 2 | $46 |
| Electromed, Inc. | 2 | $35 |
| Verona Pharma, Inc. | 2 | $35 |
| Sanofi | 1 | $26 |
| Covis Pharma GmbH | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,451 in reported general payments places this provider in the 85th percentile of 255 pulmonary disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 49 | $670,470 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 580 | $467,438 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 138 | $70,644 |
| Fasenra PenBenralizumab | 11 | $58,140 |
| TezspireTezepelumab-Ekko | 12 | $49,459 |
| Dupixent PenDupilumab | 13 | $48,710 |
| Breo ElliptaFluticasone/Vilanterol | 79 | $30,860 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 48 | $30,092 |
| Spiriva RespimatTiotropium Bromide | 52 | $26,928 |
| Pirfenidone | 13 | $25,615 |
| Arnuity ElliptaFluticasone Furoate | 42 | $13,506 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $10,057 |
| DuleraMometasone/Formoterol | 11 | $9,896 |
| Tiotropium Bromide | 25 | $9,053 |
| Atrovent HfaIpratropium Bromide | 12 | $6,201 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $10,125 | $697,398101 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $1,488 | $582,448839 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $1,561 | $89,60889 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 255 pulmonary disease providers in Connecticut.
Other pulmonary disease in Hartford
- Raj ParikhHartford$386K
- Patrick TroyHartford$385K
- Jeffrey NascimentoHartford$213K
- Daniel GerardiHartford$156K
- James PopeHartford$125K
- Anil MaggeHartford$74K
- Francoise RouxHartford$39K
- Eric ShoreHartford$35K
- John RussomannoHartford$18K
- Jordan PownerHartford$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.